Healio (5/5, Gramigna) reported, “Long-term esketamine nasal spray plus a new oral antidepressant appeared safe and tolerable among patients with treatment resistant depression,” investigators concluded in an 802-patient, “phase 3, open-label, multicenter, long-term study.” The findings were published online in the Journal of Clinical Psychiatry. (SOURCE: APA Headlines)